Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAkura Medical

About this trial

This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

Eligibility criteria

Qualifiers

The patient is 18 years of age or older and deemed medically eligible for interventional procedure, per institutional guidelines and clinical judgement

Clinical signs, symptoms and presentation consistent with acute PE

PE symptom duration ≤ 14 days

CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)

Disqualifiers

Prior PE <180 days from index procedure

Thrombolytic use within 30 days prior to baseline CTA

Pulmonary hypertension with peak pulmonary arterial pressure (PAP) > 70 mmHg by right heart catheterization

Vasopressor requirement after fluids to keep pressure at ≥ 90 mmHg

Trial design

Treatments tested in this trial

  • ATC

Treatment groups

118 Participants
are divided into 1 treatment group

Sponsors and collaborators